Medical imaging software developer MIM Software has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its molecular radiotherapy (MRT) dosimetry product.
MIM SurePlan MRT software provides quantitative SPECT reconstruction and voxel-based absorbed dose calculation through a patient's own images for personalized dosimetry measurements. It features tools for organ and tumor segmentation, deformable registration, and voxel-based dosimetry for MRT, as well as multitracer theranostics support, quantitative SPECT and planar corrections, and dosimetry reporting tools.
MRT uses radiopharmaceuticals such as Lutathera (lutetium-177 DOTATATE) and Azedra (iodine-131 iobenguane) to target tumors based on certain receptors that these tumors express.
